Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2007-01-16
2007-01-16
Hayes, Robert C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C530S399000
Reexamination Certificate
active
10442894
ABSTRACT:
NGF microencapsulation compositions having controlled release characteristics, preferably with increased stability, for the NGF component, particularly human recombinant NGF (“rhNGF”) are provided that yield enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function. Methods for making and using such compositions are also provided.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5288622 (1994-02-01), Gray et al.
patent: 5488099 (1996-01-01), Persson et al.
patent: 5589167 (1996-12-01), Cleland et al.
patent: 3218121 (1983-11-01), None
patent: 36676 (1981-09-01), None
patent: 52322 (1982-05-01), None
patent: 58481 (1982-08-01), None
patent: 88046 (1983-09-01), None
patent: 102324 (1984-03-01), None
patent: 142641 (1985-05-01), None
patent: 143949 (1985-06-01), None
patent: 172636 (1986-02-01), None
patent: 92028412 (1992-05-01), None
patent: WO 94 19020 (1994-09-01), None
patent: WO 95/33829 (1995-12-01), None
patent: WO 96 40072 (1996-12-01), None
patent: WO 97/17087 (1997-05-01), None
Mahoney et al., “Controlled Release of Proteins to Tissue Transplants for the Treatment of Neurodegenerative Disorders”, Journal of Pharmaceutical Sciences, vol. 85 (12) 1276-1281, Dec. 1996.
Angeletti et al., “Nerve Growth Factor From Mouse Submaxillary Gland: Amino Acid Sequence”Proc. Natl. Acad. Sci. USA68 (10): 2417-2420 (1971).
Apfel et al., “Nerve Growth Factor Prevents Experimental Cisplatin Neuropathy”Ann. Neurol.31: 76-80 (1992).
Apfel et al., “Nerve Growth Factor Prevents Toxic Neuropathy in Mice”Annals of Neurology29(1):87-90 (Jan. 1991).
Berman et al., “Age-Related Changes in Regional Cerebral Blood Flow and Behavior in Sprague-Dawley Rats”Neurobiol. Aging9:691-696 (1988).
Bigl et al., “The Nucleus basalis of Meynert during ageing and in dementing neuropsychiatric disorders”Brain Cholinergic Systems, Steriade and Biesold, Oxford: Oxford University Press pp. 364-386 (1990).
Bothwell et al., “Dissociation Equilibrium Constant of β Nerve Growth Factor”The Journal of Biological Chemistry252(23):8532-8536 (Dec. 10, 1977).
Canova-Davis et al., “Amino-terminal serine to glycine post-translational modification observed in nerve growth factor biosynthesized in Chinese hamster ovary cells”Peptides(Proceedings of the Thirteenth American Peptide Symposium Jun. 20-25, 1993). Hodges and Smith, Leiden The Netherlands: ESCOM pp. 230-231.
Cleland and Duenas, “Controlled Delivery of Nerve Growth Factor for Local Treatment of Neuronal Diseases”Proceed. Intl. Symp. Control. Rel. Bioact. Mater.pp. 823-824 (1997).
Cleland et al., “Stable Formulations of Recombinant Human Growth Hormone and Interferon-γ for Microencapsulation in Biodegradable Microspheres”Pharm. Res.13(10): 1464-1475 (1996).
Connolly et al., “Pit Formation and Rapid Changes in Surface and Morphology of Sympathetic Neurons in Response to Nerve Growth Factor”Journal of Cell Biology90:176-180 (Jul. 1981).
Davies, “The Neurochemistry of Alzheimer's Disease and Senile Dementia”Med. Res. Rev.3:221-236 (1983).
De Young et al., “Temperature and pH Dependence of Recombinant Human Nerve Growth Factor Dimer Dissociation”Biophys. Journal66(2):A401 (Feb. 1994).
Eppstein et al., “Biological Activity of Liposome-Encapsulated Murine Interferon γ Is Mediated by a Cell Membrane Receptor”Proc. Natl. Acad. Sci.82(11):3688-3692 (1985).
Fischer et al., “NGF Improves Spatial Memory in Aged Rodents as a Function of Age”J. Neurosci.11(7):1889-1906 (1991).
Frederickson et al., “Zinc-containing 7S-NGF Complex. Evidence From Zinc Histochemistry for Localization in Salivary Secretory Granules”Journal of Histochemistry and Cytochemistry35(5):579-583 (1987).
Greene, “A Quantitative Bioassay for Nerve Growth Factor (NGF) Activity Employing a Clonal Pheochromocytoma Cell Line”Brain Research133:350-353 (1977).
Halegoua et al., “Nerve Growth Factor Mediates Phosphorylation of Specific Proteins”Cell22:571-581 (Nov. 1980).
Hefti, F., “Nerve Growth Factor Promotes Survival of Septal Cholinergic Neurons After Fimbrial Transections”J. of Neuroscience6(8):2155-2162 (Aug. 1986).
Holland et al., “Nerve Growth Factor in Different Crystal Forms Displays Structural Flexibility and Reveals Zinc Binding Sites”J. Mol. Biol.239:385-400 (1994).
Hwang et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study”Proc. Natl. Acad Sci.77:4030-4034 (1980).
Johnson et al., “A Month-Long Effect From a Single Injection of Microencapsulated Human Growth Hormone”Nature Medicine2:795-799 (1996).
Koliatsos et al., “Human Nerve Growth Factor Prevents Degeneration of Basal Forebrain Cholinergic Neurons in Primates”Ann. Neurol.30:831-840 (1991).
Koliatsos et al., “Recombinant Human Nerve Growth Factor Prevents Retrograde Degeneration of Axotomized Basal Forebrain Cholinergic Neurons in the Rat”Exp. Neurol.112:161-173 (1991).
Korsching, S., “The role of nerve growth factor in the CNS”TINSpp. 570-573 (Nov./Dec. 1986).
Langer et al., “Biocompatibility of Polymeric Delivery Systems for Macromolecules”J. Biomed. Mater. Res.15:267-277 (1981).
Langer, “Controlled Release of Macromolecules”Chem. Tech.12:98-105 (1982).
Lofti et al., “Cerebral Ilemodynamic and Metabolic Effects of Chronic Alcoholism”Cerebrovasc. and Brain Metab. Rev.1:2-25 (1989).
McDonald et al., “New Protein Fold Revealed by a 2.3-A Resolution Crystal Structure of Nerve Growth Factor”Nature354:411-414 (1991).
Moore et al., “The Use of Hybrid Molecules in a Study of the Equilibrium Between Nerve Growth Factor Monomers and Dimers”Neurobiology5:369-381 (1975).
Mumenthaler et al., “Feasibility Study on Spray-Drying Protein Pharmaceuticals: Recombinant Human Growth Hormone and Tissue-Type Plasminogen Activator”Pharm. Res.11:12-20 (1994).
Petty et al., “The Effect of Systematically Administered Recombinant Human Nerve Growth Factor in Healthy Human Subjects”Ann. Neurol.36:244-246 (1994).
Ross et al., “Zinc alters conformation and inhibits biological activities of nerve growth factor and related neurotrophins”Nature Medicine3(8):872-878 (Aug. 1997).
Schmelzer et al., “Biochemical Characterization of Recombinant Human Nerve Growth Factor”Journal of Neurochemistry59(5):1675-1683 (1992).
Scott et al., “Isolation and nucleotide sequence of a cDNA encoding the precursor of mouse nerve growth factor”Nature302:538-540 (1983).
Shih et al., “Mutagenesis Identifies Amino-terminal Residues of Nerve Growth Factor Necessary for Trk Receptor Binding and Biological Activity”Journal of Biological Chemistry269:27679-27686 (1994).
Sidman et al., “Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid”Biopolymers22(1):547-556 (1983).
Skaper et al., “Maintenance by Nerve Growth Factor of the Intracellular Sodium Environment in Spinal Sensory and Sympathetic Ganglionic Cells”Brain Research197:379-389 (1980).
Thoenen et al., “Physiology of Nerve Growth Factor”Physiological Reviews60(4):1284-1335 (Oct. 1980).
Tiercy et al., “Early Changes in the Synthesis of Nuclear and Cytoplasmic Proteins Are Induced by Nerve Growth Factor in Differentiating Rat PC12 Cells”Journal of Cell Biology103(6):2367-2378 (Dec. 1986).
Timm et al., “Comparitive Equilibrium Denaturation Studies of the Neurotrophins: Nerve Growth Factor, Brain-derived Neurotrophic Factor, Neurotrophin 3, and Neurotrophin 4/5”Biochem
Cleland Jeffrey L.
Duenas Eileen T.
Lam Xanthe M.
Agarwal Atulya R.
Dreger Ginger R.
Genentech Inc.
Hayes Robert C.
Heller Ehrman LLP
LandOfFree
Controlled release microencapsulated NGF formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release microencapsulated NGF formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release microencapsulated NGF formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3742834